Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
3
Expiration
Dec 11, 2026
DTE
28d
Moneyness
ITM
Intrinsic
$3.01
IBRX 3 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $5.49 | +14.85% | 1 | 7 |
| Nov 20, 2026 | 7d | $5.20 | -9.25% | 21 | 20 |
| Nov 27, 2026 | 14d | $5.52 | +4.15% | 3 | 12 |
| Dec 4, 2026 | 21d | $5.50 | +0.00% | 6 | 16 |
| Dec 11, 2026 | 28d | $5.45 | +0.00% | 2 | 2 |
| Dec 18, 2026 | 35d | — | — | 0 | 20 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $5.68 | -21.11% | 10 | 11,653 |
| Mar 19, 2027 | 126d | $4.60 | -22.03% | 10 | 706 |
| Apr 16, 2027 | 154d | $5.90 | +11.53% | 10 | 50 |
| May 21, 2027 | 189d | $5.84 | +16.80% | 1 | 5 |
| Aug 20, 2027 | 280d | — | — | 0 | 0 |
| Nov 19, 2027 | 371d | — | — | 0 | 0 |
| Jan 21, 2028 | 434d | $5.90 | +1.72% | 1 | 31,192 |
| Mar 17, 2028 | 490d | $5.80 | -31.76% | 149 | 944 |
| Jan 19, 2029 | 798d | $5.92 | +2.60% | 10 | 41 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.